Genmab A (GMAB) Gross Margin (2018 - 2026)
Genmab A (GMAB) posted Gross Margin of 92.75% for Q1 2026, down 1.44% on a QoQ basis from 94.1% in Q3 2025, and down 138.0% year-over-year from 244.07% in Q1 2025.
Genmab A (GMAB) Gross Margin (2018 - 2026) Analysis & Trends
Genmab A's Gross Margin history runs 6 years deep, the most recent figure standing at 92.75% for Q1 2026.
- Quarterly Gross Margin fell 138.0% year-over-year to 92.75% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 93.86% (down 167.0% YoY) and the FY2025 annual result came in at 93.6%, down 182.0% from the prior year.
- Gross Margin was 92.75% for Q1 2026 at Genmab A, down from 94.1% in the prior quarter.
- Across five years, Gross Margin topped out at 96.02% in Q2 2024 and bottomed at 92.75% in Q1 2026.
- A 3-year average of 94.59% and a median of 94.13% in 2025 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2025 — Gross Margin plunged 206 bps — and 2026, when it tumbled 138 bps.
- Genmab A's Gross Margin stood at 95.68% in 2024, then dropped by 2 bps to 94.1% in 2025, then declined by 1 bps to 92.75% in 2026.
- Business Quant data shows GMAB's Gross Margin at 92.75% in Q1 2026, 94.1% in Q3 2025, and 93.96% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn | 92.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.75% |
| Sep 30, 2025 | 94.10% |
| Jun 30, 2025 | 93.96% |
| Mar 31, 2025 | 94.13% |
| Sep 30, 2024 | 95.68% |
| Jun 30, 2024 | 96.02% |
| Mar 31, 2024 | 95.52% |
| Sep 30, 2020 | 99.53% |
| Dec 31, 2019 | 99.31% |
| Sep 30, 2019 | -694,334,819.47% |
| Dec 31, 2018 | 100.00% |